+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
T

Actively Recruiting

Healthy Volunteer

This research aims to evaluate how active health education methods can increase the number of schoolchildren getting the HPV vaccine. The study addresses a recent drop in HPV vaccine adherence among young people in Brazil. It involves 80 schools and 5,000 students, using a stepped-wedge design where clusters of schools are randomized every two months to one of four different interventions. The study compares four approaches active training for both students and teachers, active training for students only, a nurse-led vaccination orientation session in schools, and usual care without specific interventions. Teacher training includes 30 hours of online self-instruction focused on vaccination, while students receive education and active vaccination efforts over two months. Each intervention is applied to clusters of schools in a randomized sequence. Participants are schoolchildren aged 9 to 14 years. Researchers will measure vaccination rates, including the proportion receiving at least one dose and those completing the full HPV vaccine series, along with tracking vaccination refusals among students and teachers over 12 months. The study monitors these outcomes following the interventions to understand their impact on vaccine coverage and refusal rates.

Age: 9Years - 14YearsAll GendersPhase Not Applicable
79 locations
E

Actively Recruiting

Researchers are evaluating whether low-dose colchicine, an anti-inflammatory drug, can reduce the risk of serious vascular events in patients with symptomatic peripheral artery disease PAD. This study is a randomized, double-blind, multicenter trial involving 6,150 participants, aiming to prevent events such as heart attack, stroke, cardiovascular death, severe limb ischemia, and major vascular amputation. The primary outcome measured is a combination of major adverse cardiovascular and limb events MACE and MALE. Participants are randomly assigned to receive either colchicine 0.5 mg once daily or a placebo that looks identical. The trial includes an active run-in period and will continue over a period of 3 to 5 years, during which patients take their assigned tablets daily. Both the active drug and placebo are stored securely and administered under blinded conditions so neither patients nor investigators know which treatment is given. Throughout the study, participants will be regularly monitored for cardiovascular events and limb health. Evaluations include tracking occurrences of heart attacks, strokes, hospitalization, vascular interventions, amputations, and mortality. Quality of life and physical activity are also assessed using specific questionnaires. Safety monitoring and follow-up will continue for the duration of the trial, which may last up to 5 years for each participant.

Age: 18Years +All GendersPhase 3
86 locations
I

Actively Recruiting

Researchers are evaluating the effects of lowering blood phosphate levels in adults with end-stage kidney disease ESKD who are receiving dialysis. This trial compares intensive lowering of serum phosphate towards the normal level 1.50 mmolL with a more liberal target 2.0 to 2.5 mmolL to see if it reduces death or major cardiovascular events, and improves physical health and quality of life. The study is a large, international, randomized controlled trial sponsored by The University of Queensland. Participants will be randomly assigned to one of two groups one targeting a liberal serum phosphate level where phosphate-lowering medications are only prescribed if levels exceed 2.5 mmolL, and the other aiming for an intensive target with medications used to lower phosphate to normal levels. The choice and dose of phosphate binders will be decided by the treating physician and participant. The treatment period is expected to last up to five years. During the study, participants will be monitored for cardiovascular events, death, physical health, fatigue, quality of life, and patient satisfaction. Assessments include tracking the time to cardiovascular death or major cardiovascular events, all-cause death, and quality of life using the EQ5D-5L measure. Data will be collected throughout the treatment period, with safety and effectiveness evaluated over five years.

Age: 18Years +All GendersPhase Not Applicable
126 locations
E

Actively Recruiting

Researchers are conducting a multicenter, randomized, open-label trial to study women with microprolactinomas who have not previously been treated. The study compares two dosing regimens of cabergoline CAB, a dopamine agonist used to treat prolactinomas. The goal is to evaluate remission rates and potentially improve future treatments for this condition by testing a higher dose against the current standard dose over different time periods. Participants will be randomly assigned to one of two groups. The high-dose group will receive escalating doses of oral CAB over 7 weeks to reach 3.5 mg per week, maintain this dose for about 6 months, and then gradually reduce the dose over 1 month. The standard-dose group will take a lower dose of CAB sufficient to normalize prolactin levels, adjusted as needed, for 2 years. After treatment, CAB will be withdrawn for all patients regardless of tumor size or hormone levels. During the study, participants will be closely monitored with clinical evaluations and laboratory tests to assess remission at 3, 6, and 12 months after treatment starts. Researchers will track hormone levels, tumor size, and any side effects. The total duration of involvement varies by treatment group, ranging from about 6 months to 2 years, followed by dose discontinuation. This approach aims to provide detailed information on the safety and effectiveness of the different dosing strategies.

Age: 18Years +FEMALEPhase 3
16 locations
C

Actively Recruiting

The VISIONAIRE trial studies patients with atrial fibrillation or atrial flutter who also have advanced chronic kidney disease. This phase 4, randomized clinical trial is designed to compare three blood-thinning strategies to manage the risk of blood clots in this population, aiming to understand their effects on safety and effectiveness. The trial is sponsored by Hospital Sirio-Libanes and includes 1500 participants. Participants will be randomly assigned to one of three groups full-dose warfarin adjusted to a target INR between 2.0 and 3.0, a fixed dose of 30 mg daily edoxaban, or no anticoagulation treatment. Warfarin dosing will be adjusted according to guidelines from Brazil for patients with low kidney function. The study will follow participants over a median period of 24 months to assess outcomes. During the trial, participants will be monitored regularly to evaluate both the benefits and risks of each treatment strategy. Researchers will measure primary and secondary outcomes related to efficacy and safety, including bleeding and stroke events. Follow-up evaluations will include clinical assessments and laboratory tests to track kidney function and blood clotting status throughout the study duration.

Age: 18Years +All GendersPhase 4
6 locations